Medigene Refills Its Early Pipeline By Buying Trianta Immunotherapies
This article was originally published in The Pink Sheet Daily
Executive Summary
For just under €10 million, Germany’s Medigene completes its restructuring with immunotherapy platform technologies that include dendritic cell vaccines, T-cell receptor based products and anti-T-cell monoclonal antibodies.